GeoVax Labs Inc (GOVX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:GeoVax Labs Inc (GOVX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10012
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:60
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
GeoVax Labs Inc (GeoVax) develops human vaccines for diseases caused by human immunodeficiency virus (HIV), cancer and other infectious diseases using Modified Vaccinia Ankara Virus-Like Particle (MVA-VLP) vaccine platform. The company’s vaccine development programs focus on HIV, Zika virus and hemorrhagic fever viruses (Ebola, Marburg, Lassa fever) and for cancer immunotherapy. Its advanced vaccines under development act against the clade B subtype of the HIV virus and clade C subtype. GeoVax developed its proprietary vaccine technology in collaboration with the U.S. National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC) and Emory University. GeoVax is headquartered in Smyrna, Georgia, the US.

GeoVax Labs Inc (GOVX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
GeoVax Labs Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
GeoVax Labs Inc, Medical Devices Deals, 2012 to YTD 2018 10
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
GeoVax Labs and PharmaJet Enter into Partnership 13
Geovax Labs and Emory University Enter into Partnership 14
GeoVax Labs Enters into Agreement with CaroGen 15
GeoVax Labs Enters into Agreement with Vaxeal 16
GeoVax Labs Enters into Agreement with Scripps Research Institute and Institute of Human Virology 17
GeoVax Labs Enters into Partnership with American Gene Technologies 18
GeoVax Labs Research Agreement with Georgia State University Research Foundation 19
GeoVax Labs Enters into Research Agreement with Burnet Institute 20
GeoVax Labs Enters into Co-Development Agreement with ViaMune 21
GeoVax Labs Enters into Research Agreement with Centers for Disease Control and Prevention 22
GeoVax Labs Enters into R&D Agreement with USAMRIID 23
GeoVax Labs Enters into Research Agreement with University of Georgia 24
GeoVax Labs Enters into Research Agreement with University of Pittsburgh 25
GeoVax Labs Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 26
Licensing Agreements 27
GeoVax Labs Enters into Licensing Agreement with Valneva 27
Equity Offering 28
GeoVax Labs to Issue Up to 66,666,666 Series D Convertible Preferred Stock 28
GeoVax Labs Issues 1,000 Shares in Private Placement of Series D Preferred Stock 29
GeoVax Labs Raise Funds through in Public Offering of Shares up on Exercise of Warrants 30
GeoVax Labs Raises USD6 Million in Private Placement 31
GeoVax Labs Completes Private Placement Of Shares For US$1.6 Million 32
GeoVax Completes Private Placement Of Series A Convertible Preferred Stock For US$2.2 Million 33
GeoVax Completes Second Tranche Of Private Placement Of Units For US$0.25 Million 34
GeoVax Labs Inc – Key Competitors 35
GeoVax Labs Inc – Key Employees 36
GeoVax Labs Inc – Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Recent Developments 38
Financial Announcements 38
Aug 07, 2018: GeoVax reports 2018 second quarter financial results and provides corporate update 38
May 03, 2018: GeoVax Reports 2018 First Quarter Financial Results and Development Program Updates 40
Mar 23, 2018: GeoVax Announces 2017 Year-End Financial Results 42
Nov 09, 2017: GeoVax Reports 2017 Third Quarter Financial Results and Development Program Updates 43
Aug 07, 2017: GeoVax Reports 2017 Second Quarter Financial Results Results and Provides Corporate Update 45
May 08, 2017: GeoVax Reports 2017 First Quarter Financial Results and Development Program Updates 47
Mar 24, 2017: GeoVax Reports 2016 Year-End Financial Results 48
Corporate Communications 49
Aug 14, 2018: GeoVax names David Dodd as Chairman, President and Chief Executive Officer 49
Product News 50
10/09/2017: GeoVax Chief Scientific Officer to Deliver Two Talks at World Vaccine Congress 50
08/30/2017: GeoVax Presents Preliminary Data for Cancer Vaccine 51
04/03/2017: GeoVax Awarded $658,000 NIH Grant for its HIV Vaccine Program 52
01/16/2018: GeoVax Publishes Ebola Vaccine Study Results in Nature’s Scientific Reports 53
Clinical Trials 54
Jan 23, 2017: GeoVax Announces Initiation of HIV Human Clinical Trial 54
Other Significant Developments 55
Mar 28, 2018: GeoVax Provides Vaccine Development Update 55
Mar 27, 2017: GeoVax Reports on Vaccine Development Progress 58
Appendix 60
Methodology 60
About GlobalData 60
Contact Us 60
Disclaimer 60

List of Tables
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
GeoVax Labs Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
GeoVax Labs Inc, Deals By Therapy Area, 2012 to YTD 2018 9
GeoVax Labs Inc, Medical Devices Deals, 2012 to YTD 2018 10
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
GeoVax Labs and PharmaJet Enter into Partnership 13
Geovax Labs and Emory University Enter into Partnership 14
GeoVax Labs Enters into Agreement with CaroGen 15
GeoVax Labs Enters into Agreement with Vaxeal 16
GeoVax Labs Enters into Agreement with Scripps Research Institute and Institute of Human Virology 17
GeoVax Labs Enters into Partnership with American Gene Technologies 18
GeoVax Labs Research Agreement with Georgia State University Research Foundation 19
GeoVax Labs Enters into Research Agreement with Burnet Institute 20
GeoVax Labs Enters into Co-Development Agreement with ViaMune 21
GeoVax Labs Enters into Research Agreement with Centers for Disease Control and Prevention 22
GeoVax Labs Enters into R&D Agreement with USAMRIID 23
GeoVax Labs Enters into Research Agreement with University of Georgia 24
GeoVax Labs Enters into Research Agreement with University of Pittsburgh 25
GeoVax Labs Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 26
GeoVax Labs Enters into Licensing Agreement with Valneva 27
GeoVax Labs to Issue Up to 66,666,666 Series D Convertible Preferred Stock 28
GeoVax Labs Issues 1,000 Shares in Private Placement of Series D Preferred Stock 29
GeoVax Labs Raise Funds through in Public Offering of Shares up on Exercise of Warrants 30
GeoVax Labs Raises USD6 Million in Private Placement 31
GeoVax Labs Completes Private Placement Of Shares For US$1.6 Million 32
GeoVax Completes Private Placement Of Series A Convertible Preferred Stock For US$2.2 Million 33
GeoVax Completes Second Tranche Of Private Placement Of Units For US$0.25 Million 34
GeoVax Labs Inc, Key Competitors 35
GeoVax Labs Inc, Key Employees 36
GeoVax Labs Inc, Subsidiaries 37

List of Figures
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
GeoVax Labs Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
GeoVax Labs Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[GeoVax Labs Inc (GOVX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • GVC Holdings PLC:企業の戦略・SWOT・財務情報
    GVC Holdings PLC - Strategy, SWOT and Corporate Finance Report Summary GVC Holdings PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • CooperSurgical Inc:企業のM&A・事業提携・投資動向
    CooperSurgical Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's CooperSurgical Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • Amicus Therapeutics Inc (FOLD):企業の財務・戦略的SWOT分析
    Amicus Therapeutics Inc (FOLD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • CIMIC Group Ltd (CIM):企業の財務・戦略的SWOT分析
    CIMIC Group Ltd (CIM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • HUYA Bioscience International LLC-製薬・医療分野:企業M&A・提携分析
    Summary HUYA Bioscience International LLC (HUYA) is a developer of early and late stage drug candidates. The company’s pipeline products comprise HBI-8000, HBI-3000, and HBI-3802. Its HBI-8000 is a novel oral inhibitor of histone deacetylases; HBI-3000 is a channel blocker for the treatment of arrhy …
  • NorthWestern Corporation:発電所・企業SWOT分析
    NorthWestern Corporation - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key empl …
  • Viavi Solutions Inc
    Viavi Solutions Inc - Strategy, SWOT and Corporate Finance Report Summary Viavi Solutions Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Storebrand ASA:企業のM&A・事業提携・投資動向
    Storebrand ASA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Storebrand ASA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Chaman Lal Setia Exports Ltd:企業の戦略・SWOT・財務情報
    Chaman Lal Setia Exports Ltd - Strategy, SWOT and Corporate Finance Report Summary Chaman Lal Setia Exports Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Electrocomponents plc (ECM):企業の財務・戦略的SWOT分析
    Electrocomponents plc (ECM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Peloton Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Peloton Therapeutics Inc (Peloton) is a clinical-stage pharmaceutical company that develops oral medicines and novel therapies for oncology. Its portfolio of pipeline products includes PT2977, PT2567 and PT2385. The company develops its products for the treatment of pulmonary arterial hypert …
  • CellaVision AB (CEVI):医療機器:M&Aディール及び事業提携情報
    Summary CellaVision AB (CellaVision) is a medical technology company that provides digital solutions for medical microscopy in hematology. The company helps hematology laboratories improve and transform the analysis of blood and other body fluids. It has expertise in digital image analysis, automate …
  • Tubacero S. de RL de CV:企業の戦略・SWOT・財務情報
    Tubacero S. de RL de CV - Strategy, SWOT and Corporate Finance Report Summary Tubacero S. de RL de CV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • ZAPPALLAS, Inc. (3770):企業の財務・戦略的SWOT分析
    ZAPPALLAS, Inc. (3770) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Petroleos Mexicanos (PEMEX):戦略・SWOT・企業財務分析
    Petroleos Mexicanos (PEMEX) - Strategy, SWOT and Corporate Finance Report Summary Petroleos Mexicanos (PEMEX) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Diagnostics For All Inc:企業の製品パイプライン分析
    Summary Diagnostics For All Inc (DFA) is a drug development company that develops and commercializes of new technology and practical diagnostic devices for diagnostic companies. The company uses patterned paper technology to create electrochemical clinical chemistry assays, immunoassays, assays, and …
  • MISC Bhd (MISC):石油・ガス:M&Aディール及び事業提携情報
    Summary MISC Bhd (MISC), a subsidiary of Petroliam Nasional Berhad (Petronas), is an international energy shipping and maritime conglomerate. The company is a fully integrated maritime, offshore floating solution, heavy engineering and logistics service provider. Its principal business activities in …
  • Virginia Electric and Power Company:発電所・企業SWOT分析
    Virginia Electric and Power Company – Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information …
  • Exosome Diagnostics Inc:企業の製品パイプライン分析
    Summary Exosome Diagnostics Inc (Exosome Diagnostics) is a provider of diagnostic solutions. The company develops, designs, manufactures and markets biofluid-based molecular diagnostic tests and products for use in personalized medicine. Exosome Diagnostics’ services comprise miRNA profiling, mRNA p …
  • European Institute of Oncology-製薬・医療分野:企業M&A・提携分析
    Summary European Institute of Oncology (IEO) is a research institute that conducts clinical and scientific research on cancer prevention, early diagnosis and treatment of cancer. The institute offers medical care services for breast tumors, lung tumors, cervical tumors, endometrial tumors, thoracic …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆